• Halozyme Therapeutics Inc., of San Diego, reported positive results from a study in patients with Type I diabetes that receive their insulin therapy via pumps. The Phase Ib randomized, double-blind, crossover design study is intended to determine insulin pharmacokinetics, glucodynamics, safety and tolerability of rHuPH20 (recombinant human hyaluronidase) as a single injection prior to the start of three days of NovoLog insulin aspart pump infusion therapy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter